On Friday, Loews Corporation (NYSE:L)’s shares declined -0.96% to $39.27.
Diamond Offshore is owned 53% by Loews Corporation (L).
Diamond Offshore Drilling, Inc. declared that it will issue its future fleet status reports each calendar quarter concurrent with the release of its quarterly earnings. The Company has historically issued its fleet status reports on a monthly basis. The change from monthly to quarterly reporting is intended to better protect sensitive customer and contract information in light of competitive dynamics in the offshore drilling industry.
Loews Corporation, through its auxiliaries, operates as a commercial property and casualty insurance company primarily in the United States. The company offers administration and professional liability insurance and risk administration services, and other specialized property and casualty coverages; commercial surety and fidelity bonds; and warranty and alternative risk services primarily for vehicles and portable electronic communication devices. Its commercial’s property insurance products comprise standard and excess property, marine, and boiler and machinery coverages; and casualty insurance products comprise workers compensation, general and product liability, commercial auto, and umbrella coverage’s.
Accuray Incorporated (NASDAQ:ARAY)’s shares dropped -2.46% to $7.13.
Accuray Incorporated (ARAY) will continue rebounding in the next month.
optionMONSTER’s Heat Seeker system detected the purchase of 1,000 July 7 calls for $0.37 and the sale of 1,000 July 6 puts for $0.05. Volume was far above the open interest in each strike, showing that this is new positioning.
This combination trade is highly bullish because a rally would boost the price of the long calls while decreasing the value of the puts that were sold . But the opposite will occur if the stock drops, and the trader will be on the hook to buy shares if they fall below $6 by expiration in mid-July. (See our Education section)
ARAY is up 0.29 percent to $7 in early trade. The radiation-therapy company gapped down from above $8 after reporting quarterly results on April 30 but has been climbing off support at the $6 level this month.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, in addition to enables delivery of precise, high dose radiation while patients breathe normally.
At the end of Friday’s trade, HomeAway, Inc. (NASDAQ:AWAY)‘s shares dipped -1.99% to $31.06.
HomeAway, Inc. (AWAY), the world leader in vacation rentals, declared a partnership with Dubai’s Department of Tourism and Commerce Marketing (Dubai Tourism) to promote Dubai’s vacation homes to the world and Dubai as a destination to HomeAway(R) travelers.
The relationship enhances HomeAway’s position in the Middle East and opens Dubai up to the millions of families and groups of travelers from around the globe who book their vacation rental accommodations via HomeAway. HomeAway and Dubai Tourism will work together to strengthen the vacation homes sector in Dubai by raising awareness of and providing support to the many licensed vacation homes operators in the Emirate. Additionally, the two organizations are planning joint traveler-focused campaigns, leveraging Dubai’s world-class marketing team and HomeAway’s global strength in the vacation homes sector.
HomeAway, Inc., together with its auxiliaries, operates an online vacation rental property marketplace that enables property owners and managers to market properties for rental to vacation travelers. The company’s portfolio comprises vacation rental Websites, such as HomeAway.com, VRBO.com, and VacationRentals.com in the United States; HomeAway.co.uk and OwnersDirect.co.uk in the United Kingdom; HomeAway.de in Germany; Abritel.fr and Homelidays.com in France; HomeAway.es and Toprural.com in Spain; AlugueTemporada.com.br in Brazil; HomeAway.com.au and Stayz.com.au in Australia; and Bookabach.co.nz in New Zealand.
POZEN Inc. (NASDAQ:POZN), ended its Friday’s trading session with 4.42% gain, and closed at $11.57.
POZEN Inc. (POZN) a pharmaceutical company committed to developing medicine that transforms lives, recently declared the acquisition of Tribute Pharmaceuticals Canada Inc. (TBUFF), a Canadian specialty pharmaceutical company, in a transaction valued at about US$146 million. Upon completion of the acquisition, which is predictable to occur in the fourth quarter of 2015, the combined company will be named Aralez Pharmaceuticals plc (“Aralez” or the “Company”) and domiciled in Ireland. Upon closing, Aralez is predictable to trade on NASDAQ and TSX.
The acquisition will create a premier specialty pharmaceutical company with a broad portfolio of commercial products and a growth plan focused on innovative products and acquisitions and the commercialization of portfolio products in the United States and Canada. The Company will also be well positioned to expand its foreign presence through potential international sales and licensing, manufacturing and product development.
Recently, POZEN’s lead proprietary product is YOSPRALA™, a coordinated-delivery tablet designed to provide the cardiovascular benefit of aspirin while reducing its gastrointestinal side effects. POZEN also has two commercial pain products, VIMOVO® and Treximet®, which are marketed by partners worldwide. Tribute’s highly complementary portfolio comprises Fibricor®, Bezalip® SR and Visken®/Viskazide® for various cardiovascular indications; Cambia® and Fiorinal® and Fiorinal® C for acute migraines and tension headaches, respectively; and a range of other specialty products. Tribute also is pursuing active and ongoing business development activities.
POZEN Inc., a pharmaceutical company, develops products for the treatment of acute and chronic pain, and pain related conditions in the United States and internationally. Its principal PA product candidates comprise PA32540 and PA8140 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have accomplished clinical development in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
